Results 131 to 140 of about 178,192 (271)

Hydrogen for heavy industry

Cell Reports Sustainability
Richard Thompson, Melissa Plail, Lu Liu
doaj   +1 more source

Contributors' Notes/Notas sobre las autoras

Iberoamericana: Nordic Journal of Latin American and Caribbean Studies, 2012
Editorial Team
doaj   +1 more source

Editorial Team changes: thanking you for your service! [PDF]

Psychiatr Psychol Law
Nolan MA.
europepmc   +1 more source

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

Arthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel Lovell, Nicolino Ruperto   +28 more
wiley   +1 more source

Abstracts/Resúmenes

Iberoamericana: Nordic Journal of Latin American and Caribbean Studies, 2012
Editorial Team
doaj   +1 more source

Tips for quality publishing; lessons from the neuroscience editorial team. [PDF]

Neuroscience
Cirulli F, Dangarembezi R, de Lafuente V, Hannan AJ, Kentner AC, Mima T, Morris L, Spencer SJ, Wu LJ, Zhang C.   +9 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Editorial Team [PDF]

Cadernos de Pesquisa Interdisciplinar em Ciências Humanas, 2014
openaire   +3 more sources

Editor's Farewell/Despedida del Editor

Iberoamericana: Nordic Journal of Latin American and Caribbean Studies, 2009
Jaime Behar
doaj   +1 more source

Upcoming International Conference: Heidegger, Daoism, and Intercultural Thinking Today

Filozofia
Institute of Philosophy, Slovak Academy of Sciences, v.v.i.
Editorial Team
doaj